

Speech measures associated with the course of symptoms severity in patients with MDD

Submitter Felix Menne

Affiliation ki:elements GmbH, Saarbrücken, Germany

SUBMISSION DETAILS

I agree to provide poster pdf for attendee download. Yes

Methodological Issue Being Addressed Evaluating treatment effects in psychiatry often relies on subjective assessments, like questionnaires, which can introduce bias and limit diagnostic accuracy—particularly in clinical trials and personalized treatment contexts. Objective measures are needed to enable a more accurate, transdiagnostic approach to mental health. Automated speech analysis shows promise as a non-invasive, objective tool for tracking affective and behavioral changes.

However, developing scalable and sensitive speech measures that reliably capture subtle fluctuations in symptom severity remains a challenge but are crucial for enhancing clinical trials and supporting their use in relapse prevention, monitoring, and treatment assessment, ultimately paving the way for broader adoption in psychiatric practice.

Introduction This study aimed to evaluate the potential of speech measures to monitor short-term changes in depressive symptoms in individuals with Major Depressive Disorder (MDD), compared to healthy controls. Specifically, we sought to determine whether certain speech features reflect symptom fluctuations over time and distinguish individuals with increasing versus decreasing symptom severity. This approach could indicate whether speech biomarkers could be employed for tracking symptom progression and treatment response, with potential applications in early relapse detection in clinical practice.

Methods Participants included 22 individuals with MDD and 22 healthy controls, recruited at the Karl-Jaspers Clinic of Psychiatry, University Hospital Oldenburg, Germany. Depressive symptoms were assessed using the Beck Depression Inventory (BDI) at two points, two weeks apart. Based on BDI changes, participants were grouped as "decliners" (higher BDI scores at the second time point, $n=13$) and "non-decliners" (lower or unchanged BDI scores, $n=31$). Automated speech analysis was conducted on recordings from both time points, examining specific speech features. Participants completed three storytelling tasks (positive, neutral, and negative) and a "PaTaKa" task, which involved rapid repetition of the syllables "pa-ta-ka" for 10 seconds. The primary analysis focused on detecting significant differences in speech characteristics between decliners and non-decliners, assessing speech biomarkers' sensitivity to short-term symptom changes. Group differences were evaluated using the non-parametric Kruskal-Wallis test, with Benjamini-Hochberg correction applied to p values.

Results The change in BDI between T0 and T1 was significant within the groups of decliners ($p<0.001$) and non-decliners ($p=0.01$). After adjusting for multiple comparisons, no significant

group differences were found in storytelling-based speech features between the two groups. However, significant differences were observed between decliners and non-decliners in temporal features derived from the PaTaKa task (see Table 2).

Conclusion These findings suggest that temporal features from the PaTaKa task are more sensitive to short-term changes in depressive symptoms than storytelling-based features. This heightened sensitivity may result from the PaTaKa task's focus on motor coordination and speech timing, which directly reflect psychomotor slowing—a core symptom of depression. By isolating rhythm and articulation speed, the PaTaKa task effectively captures subtle psychomotor changes that may go undetected in more complex tasks. Also, psychomotor symptoms might be more sensitive to treatment response than other symptoms such as anhedonia. These results underscore the importance of task selection in developing speech biomarkers for monitoring symptom progression in MDD.

Co-Authors

Felix Menne¹, Elisa Mallick¹, Johannes Tröger¹, Alexandra König¹,
Janna Schulze², Diana Immel², Simon Barton², René Hurlemann²

¹ ki:elements GmbH, Saarbrücken, Germany

² Dept. of Psychiatry at Karl-Jaspers Clinic, School of Medicine & Health Sciences, Carl von Ossietzky University of Oldenburg

Keywords

Keywords
depression
speech
speech biomarkers
method comparison
disease monitoring

Guidelines I have read and understand the Poster Guidelines

Disclosures The authors report no conflicts of interest for this work

Related Tables and Supporting Materials 20241113_ISCTM2025_Tables.docx